Needham & Company LLC Reiterates “Buy” Rating for OrthoPediatrics (NASDAQ:KIDS)

OrthoPediatrics (NASDAQ:KIDS)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued on Friday,Benzinga reports. They presently have a $42.00 price objective on the stock. Needham & Company LLC’s price target suggests a potential upside of 63.30% from the company’s current price.

KIDS has been the topic of several other research reports. Truist Financial lowered their target price on shares of OrthoPediatrics from $34.00 to $28.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. JMP Securities reaffirmed a “market outperform” rating and set a $50.00 price objective on shares of OrthoPediatrics in a research report on Friday, September 13th.

OrthoPediatrics Stock Performance

Shares of NASDAQ KIDS traded down $1.77 during trading on Friday, reaching $25.72. 367,372 shares of the company traded hands, compared to its average volume of 135,689. The company has a current ratio of 4.90, a quick ratio of 1.96 and a debt-to-equity ratio of 0.03. The stock has a market cap of $622.78 million, a P/E ratio of -20.91 and a beta of 1.16. The firm’s fifty day simple moving average is $27.76 and its 200 day simple moving average is $29.80. OrthoPediatrics has a 12-month low of $24.02 and a 12-month high of $36.23.

Insiders Place Their Bets

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 10,000 shares of OrthoPediatrics stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $29.30, for a total value of $293,000.00. Following the completion of the sale, the general counsel now directly owns 77,304 shares of the company’s stock, valued at approximately $2,265,007.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its position in shares of OrthoPediatrics by 85.1% during the 1st quarter. BNP Paribas Financial Markets now owns 12,414 shares of the company’s stock valued at $362,000 after acquiring an additional 5,707 shares in the last quarter. Quantbot Technologies LP boosted its holdings in shares of OrthoPediatrics by 180.8% in the first quarter. Quantbot Technologies LP now owns 7,091 shares of the company’s stock worth $207,000 after buying an additional 4,566 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in OrthoPediatrics during the 1st quarter valued at $178,000. Vanguard Group Inc. boosted its position in OrthoPediatrics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 883,827 shares of the company’s stock worth $25,772,000 after acquiring an additional 11,100 shares during the period. Finally, EntryPoint Capital LLC increased its stake in OrthoPediatrics by 56.9% in the 1st quarter. EntryPoint Capital LLC now owns 2,783 shares of the company’s stock valued at $81,000 after buying an additional 1,009 shares during the period. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.